SciSparc says US publishes patent application for MDMA-PEA combo targeting PTSD

• SciSparc flagged U.S. publication of a patent application on combining MDMA with N-acylethanolamines such as PEA for PTSD treatment.
• Application also targets anxiety, eating disorders; focuses on dosing, side effects, potency, therapeutic window for the MDMA-PEA approach.
• NeuroThera-Clearmind collaboration now totals 13 published patent applications worldwide, building an IP position in psychedelic-derived CNS programs.
• Disclosure follows FDA’s July 14, 2026 final guidance on clinical investigations for psychedelic drugs, explicitly covering MDMA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608240851PRIMZONEFULLFEED9814867) on August 24, 2026, and is solely responsible for the information contained therein.